Related to this topic: Leaflets | Support | Patient+ | UK Guidelines | News | Weblinks | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

PUVA

PUVA stands for Psoralen and UVA treatment. Psoralens are found in plants and can be sensitized when taken either orally or when applied topically. Interestingly, they were used for this purpose in ancient Egypt but have only been commercially manufactured in the last four decades.
When used with UVA (long wave radiation) they allow for a lower dose of UVA.

PUVASOL is the use of psoralens with natural sunlight in areas such as India - research so far suggests it may be as good as conventional therapy.

Indications
Method of action

It remains a mystery as to why psoralens with UVA work in the above conditions but it has been postulated to relate to modulation of the skins immune system.1

How is PUVA administered?
  • Psoralen taken orally one hour before UVA treatment.
  • If patient is unable to tolerate oral psoralens some hospitals provide a bathing system or topical psoralens e.g. gel based preparations.
  • Topical therapy with psoralens is not associated with adverse effects such as nausea and vomiting seen with oral psoralens.
  • During sessions patients need to wear protective goggles and UVA protective goggles must be worn for 24 hours following the treatment.
  • Clothes only need to be removed from area to be treated, but groin protection is required.
  • UVA treatment given 2-3x per week for about 12 weeks - in a light box.
  • Once course finished may need maintenance therapy with one session per week.
  • Avoid exposure to sunlight for 24 hours after the session.
Summary of special precautions required before PUVA treatment (see above)
  1. Eye protection - wear goggles
  2. Groin protection - wear protective shield/garment
  3. Skin and eye protection for 24 hours following session of PUVA
Adverse effects

Adverse effects from oral psoralen

  • Nausea and vomiting - caused by psoralens and reduced if taken with food; common reason for stopping treatment
  • Headache and dizziness

Adverse effects from combined psoralen and UVA

  • Sunburn (phytotoxic erythema) and blistering - occurs 2-3 days after treatment and more often in fair skinned patients
  • Dryness of skin with itching
  • Tanning - lasts months (all patients)
  • Keratitis - thus eyes need to be shielded during therapy

Adverse effects resulting from recurrent treatments

  • Enhancement of aging changes of the skin - this includes freckling and wrinkling and occurs with extensive or prolonged treatments
  • Increased skin neoplasia risk - e.g. melanoma and non-melanoma; again risk is higher with extensive and prolonged treatments
Use in specific conditions

Psoriasis

  • Used in older patients and those with severe psoriasis.
  • Chronic-plaque type psoriasis is associated with up to 100% clearance.
  • Efficacy is enhanced when combined with UVB or medications such as methotrexate (especially pustular and erythrodermic forms).
  • PUVA therapy has been compared to narrow band UVB therapy in a randomised controlled trial which reported that the former is more effective.2

Eczema or dermatitis

  • Moderate to severe eczema only - clearance in up to 75%

Mycosis fungoides

  • Rare form of cutaneous T-cell lymphoma.
  • PUVA can clear the disease but recurrence occurs in half of patients - with 30-50% remaining free of neoplasia at ten years.3
  • Requires ongoing treatment over many years and thus may be associated with skin damage and neoplasia.3

Vitiligo

PUVA can lead to repigmentation in areas where there is complete loss of pigmentation - but results are variable.


Document references
  1. Wolf P, Nghiem DX, Walterscheid JP, et al; Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis. Am J Pathol. 2006 Sep;169(3):795-805. [abstract]
  2. Yones SS, Palmer RA, Garibaldinos TT, et al; Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol. 2006 Jul;142(7):836-42. [abstract]
  3. Querfeld C, Rosen ST, Kuzel TM, et al; Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005 Mar;141(3):305-11. [abstract]
Acknowledgements EMIS is grateful to Dr Gurvinder Rull for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2008.
DocID: 2688
Document Version: 21
DocRef: bgp24558
Last Updated: 29 May 2008
Review Date: 29 May 2010

Patient Experience


















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site










Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page